Released Oct 28, 2020, before the open
10-Q filed Oct 29, 2020, 29 days after period end · 0000917520-20-000047
Q3 2020 · 10-Q
Revenue$370.23M$370.23M −2.3% vs Q3 2019+43.1% vs Q2 2020
Net Income$32.34M$32.34M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted$0.38$0.38 N/M vs Q3 2019no prior Q2 2020 on file
Gross Profit$235,421,000−0.4%
Operating Income$57,542,000N/M
Operating Cash Flowderived$69,639,000+8.4%
Free Cash Flowderived$62,912,000+24.2%
Margins · derived
Gross margin63.6%+1.2 pt vs Q3 2019
Operating margin15.5%+21.0 pt vs Q3 2019
Net margin8.7%+16.0 pt vs Q3 2019
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $370.23M | $379.10M | $365.85M | $278.83M |
| Net Income | $32.34M | -$27.61M | $13.30M | $3.16M |
| EPS Diluted | $0.38 | -$0.32 | $0.15 | $0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR